Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT
Become equipped to navigate preclinical and clinical stages of development for oral lipid-based formulations.
Register Free: https://www.pharmtech.com/pt_w/lipid-based-formulations
Event Overview:
Molecular weight confirmation is a critical analytical workflow for the development of therapeutic oligonucleotides. This webinar demonstrates oligo molecular confirmation and simple characterization by LC/MS. The combination of user-friendly software, robust hardware, and unique column chemistry enables routine molecular weight confirmation for oligos of varying lengths and modifications.
Key Learning Objectives:
Who Should Attend:
Speakers:
René Holm
Professor of Pharmacy
University of Southern Denmark
René Holm, is a pharmaceutical expert who received his training and PhD from the University of Copenhagen in 1998 and 2002, respectively. He previously worked with Lundbeck. Since 2016, he has worked with Janssen. Dr Holm has worked in various fields, including physical chemistry, material science, and pharmaceutical development. He has co-authored more than 200 original articles and is currently a professor in pharmaceutical physical chemistry at the University of Southern Denmark.
Guillaume Enderlin
Senior Manager, Pharmaceutical Development
Catalent Beinheim
Guillaume Enderlin is senior manager of pharmaceutical development at the Catalent Beinheim site (France). He has worked for 12 years in softgel R&D, from formulation to manufacturing development process, building expertise to cover the whole Rx pharmaceutical development process. Guillaume is a pharmacist (PharmD) and has a Master’s degree in pharmaceutical engineering.
Christel Bergström
Professor, Molecular Pharmaceutics
Uppsala University Sweden
Christel Bergström is a professor of molecular pharmaceutics at Uppsala University, and is an adjunct professor at Monash University. She leads a research group on drug delivery for challenging compounds and has published over 100 articles. Bergström directs The Swedish Drug Delivery Center and plays key roles in the Nordic POP initiative. In 2019, she founded Enphasys AB, focusing on animal-free drug absorption models.
Ben J. Boyd
Professor, Drug Delivery Disposition & Dynamics
University of Copenhagen & Monash Institute of Pharmaceutical Sciences
Prof. Benjamin Boyd is a colloid and physical chemist with a PhD from the University of Melbourne. With industry experience in explosives and pharmaceuticals, he holds an academic position at Monash University and recently received a Novo Nordisk Laureate Research Fellowship at the University of Copenhagen. His research focuses on lipids, lipid self-assembly, and pharmaceutical systems, including synchrotron-based characterization. Prof. Boyd is also the President of the Controlled Release Society.
Lisa Caralli
Senior Director of Scientific Advisory
Catalent
Lisa Caralli is the senior director of scientific advisory at Catalent, overseeing small molecule and peptide scientific support for North America. She has over 30 years of industry experience in pharmaceutical research and development, with a focus on early-phase approaches to the chemistry manufacturing and control of small molecules and peptides. Lisa has held previous product development positions at Ionis Pharmaceuticals, Amylin Pharmaceuticals, and the Immune Response Corporation. She holds a BS in biochemistry from the University of California at Davis.
Register Free: https://www.pharmtech.com/pt_w/lipid-based-formulations
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.